Zeposia – March ACTRIMS Display Banners Conference – 27441
ACTRIMS eBook
Focus on MS MAY 2022v2.indd
DMTs Lower Multiple Sclerosis Relapse Risk During Reproductive Therapy
In women with multiple sclerosis (MS) and clinically isolated syndrome (CIS), continuing disease...
Spinal Cord Atrophy Indicates “Silent Progression”
In patients in the earlier stages of MS, an accelerated rate of spinal cord atrophy can indicate...
White Matter Iron Rim Lesions Predict Worse Disability in Multiple Sclerosis
“Identifying an accurate prognostic biomarker in individuals with multiple sclerosis (MS) is...
Ozanimod Safe & Effective in DAYBREAK Open-Label Extension
For patients with multiple sclerosis (MS), ozanimod provides continued control of disease activity...
Fibulin-2, An Extracellular Matrix Remyelination Inhibitor
For a study, the researchers sought to assess FBLN2 expression in MS and EAE lesions to see if the ECM molecule could alter oligodendrocyte maturation and remyelination. The study team discovered elevated levels of FBLN2 in EAE...
Sex, Hormones, and Age Interactions in MS Prognosis
The researchers sought to examine aging-related mechanisms in MS prognosis for a study. They also sought to determine sex-specific elements that influence MS prognosis and explore the link between sex, hormones, and aging in MS...
Use of Electronic Health Records as Prognostic Indicator
For a study, the researchers sought to undertake 2 analyses. They combined EHR data with gold-standard data from a well-established clinic-based research registry. First, they used a 2-stage process to develop models that...
Cognitive Function Improvement in the Patients With MS
For a study, the researchers sought to compare the cognitive effects of active vs sham tDCS combined with adaptive cognitive training (aCT) administered as an at-home intervention in adults with MS in a randomized...
Serum Neurofilament For Gray Matter Atrophy And Clinical Impairment in MS
For a study, the researchers examined the relationship between sNfL levels throughout a 2-year period and clinical disability and gray matter (GM) atrophy after 10 years in early relapsing-remitting MS (RRMS) patients. A total...
Benefits of Disease-Modifying Therapy in MS Patients
For a study, the researchers sought to forecast the conditional average treatment effect (CATE) for people on anti-CD20 monoclonal antibodies and laquinimod for a study. For this, researchers used a multitask multilayer...
